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The myocardial reperfusion following ischemia leads to the ischemic vasodilation by aﬀecting the release of various vasoactive
substances, such as free radicals, NO, and histamine. In addition, some evidences suggest that glucagon itself may alter the release
of those substances. In this study, we investigated the ischemic vasodilation of the isolated rat heart, as well as the concentrations
of NO, TBARS, and histamine in the coronary venous eﬄuent either in the presence or in the absence of glucagon. Our results
showed that in the presence of glucagon, there was a faster restoration of coronary perfusion pressure during ischemic vasodilation
compared to the absence of glucagon (124 ± 5.6v e r s u s8 1± 5.2s) with no apparent changes in TBARS concentration. The
glucagon’sadministrationleadstothedecreasedreleaseofhistaminebyapproximately35%.BiphasicreleaseofNOinthepresence
of glucagon initially showed augmentation by 60%, followed by the signiﬁcant attenuation of 45%.
1.Introduction
Although the myocardial reperfusion following ischemia
can produce the salvage of the ischemic tissue, it may
also contribute not only to the endothelial dysfunction and
the myocardial cellular injury, but it also may change the
release of the biologically active substances, such as the
endothelium-derived relaxing factor (NO) [1]. Even though
NO obtained from L-arginine is a free radical per se, it also
can quench other free radicals, including the superoxide
radicals and it thereby protects both the endothelial cells and
the cardiac myocytes [2, 3]. In addition, NO may stabilize
mast cells and inhibit the release of histamine from the both
isolated and the resident cardiac mast cells, thus inﬂuencing
the postischemic myocardial injury [4–6]. Thus, low doses of
NO appear to play a key protective role from the myocardial
ischemia-reperfusion injury. However, high concentrations
of NO exert highly toxic and harmful eﬀect during the
ischemia-reperfusion injury [3, 7–9]. Beside the fact that
NO may stabilize the cardiac mast cells and it consequently
decreases the histamine release [4, 5, 10], earlier results
[11] showed a positive feedback relationship between NO
and histamine in the regulation of both coronary ischemic
vasodilation and the coronary autoregulation.
In our previous work, we evaluated both the dynamic
response and the biomechanical properties of the isolated
blood vessels in the presence of NO precursor, L-arginine
[12]. Our results demonstrated that some relaxation, such
as the increase in the diameter of the blood vessel, was
evident in the presence of L-arginine. At the same time,
the development of the pressure was signiﬁcantly faster
compared to the group without the L-arginine. The analysis
of the biomechanical parameters, such as the stress-strain
and the shear stress, suggested that the isolated blood vessel
became more rigid in the presence of L-arginine.
The myocardial ischemia and the reperfusion have also
been suggested to increase the histamine production [13].
The histamine not only exists (to a great extent) within
the mast cells and the basophilic leukocytes, but it also
could be released by the endothelial cells, the aggregating
platelets,lymphocytesandmonocytes/macrophages[14,15].
High concentrations of the histamine are present in the
cardiac tissue of most animal species, including humans [13]
provoking various cellular functions via the stimulation of2 Journal of Biomedicine and Biotechnology
four diﬀerent G-protein-coupled receptors (H1,H 2,H 3,a n d
H4). The stimulation of the H2 receptors by the histamine
induces both positive inotropic and positive chronotropic
eﬀects [16, 17]. It has been shown that the blockage of the
histamine H2 receptors improved the anaerobic metabolism
of the myocardium in the ischemic heart disease that has
been associated with the reduced myocardial oxygen con-
sumption demonstrating the highly beneﬁcial eﬀect against
theischemia-reperfusioninjury.Moreover,theantagoniststo
the H2-histamine receptors in the mast cells of the heart may
reducetheactivityofthemastcells,thereby;theymayreduce
the release of the mast cell’s mediators [13, 18, 19]. Even
though the blockage of the histamine H2 receptors limited
infarct size, the inhibition of the histamine H1 receptors did
not demonstrate this beneﬁcial eﬀect [13]. In the heart, the
stimulation of the H1 receptors with histamine impairs the
atrioventricular (AV) conduction, thus contributing to the
development of the ventricular ﬁbrillation in the myocardial
ischemia-reperfusion injury [20, 21]. Furthermore, the mast
cells play a role in the generation of the reactive oxygen
species (ROS), such as superoxide anion and hydrogen
peroxide, that are responsible for the further increased
release of the histamine from the mast cells and vice versa
[6]. The histamine eﬀects on the coronary arteries are the
result of the multiple actions of this molecule on both
smooth muscle cells and the endothelium. Some reports
showed diﬀerent eﬀects of the histamine including both
the relaxation and the constriction of the coronary vessels
depending on species, dose of the histamine, the diameter
of the blood vessels and the initial vessel’s tone, as well as the
relative location within the coronary circulation [22].
T h eg l u c a g o ni sa ne n d o g e n o u sp o l y p e p t i d eh o r m o n e
that exerts both positive inotropic and the chronotropic
eﬀects on the myocardial tissue [23, 24]. The investigations
oftheglucagoninﬂuenceonthetransportoftheradiolabeled
histamine in the isolated guinea pig heart demonstrated
the elevation of the histamine transport in the presence of
glucagon [25, 26]. Previous ﬁndings showed that the cardiac
anaphylactic crisis was markedly reduced in the presence of
glucagon. Furthermore, these data suggested that the antiar-
rhythmic action of glucagon during the cardiac anaphylaxis
involved the inhibition of histamine release, the vasodilation
of the coronary vessels, the increase in the automaticity
of the sinoatrial node, and the enhancement of the atri-
oventricular conduction velocity [27]. Moreover, it has been
demonstratedthattheglucagoninﬂuencedtheaccumulation
of histamine in the vesicles of enterochromaﬃn-like cells
[28]; however, until now there have not yet been reported
data explaining the glucagon-induced stimulation of the
histamine storage in the heart cells.
We postulated that glucagon can aﬀect the changes
of the coronary perfusion pressure during the ischemia-
reperfusion, by altering the release of NO and/or histamine
in the heart. Therefore, in the present study, we investigated
the changes in the coronary perfusion pressure during
the ischemia-reperfusion period, as well as the concentra-
tions of nitric oxide, thiobarbituric acid reactive substances
(TBARS), and histamine either in the presence or in the
absence of glucagon in the coronary venous eﬄuent of the
isolated rat heart. Here, we applied the experimental model
and originally developed mathematical procedures (12) to
describe the dynamic response of the coronary blood vessels.
2.MaterialandMethods
All experiments were performed according to EU
(86/609/EEC) and the Local ethical guidelines. Wister
rats of both sexes (200–250g body weight) were killed by
the cervical dislocation. The rat hearts were rapidly isolated
and retrogradely perused via the aorta, according to the
Langendorﬀ’s technique at a constant ﬂow (7-8mL/min/g
wt) of the perfusion buﬀer containing (in mM): NaCl 118.1,
KCl 4.7, MgSO4 1.66, NaHCO3 24.88, KH2PO4 1.18, glucose
5.5, sodium pyruvate 20, CaCl2× 2H2O 2.52. The perfusate
was continuously bubbled with 95% O2 and 5% CO2,w i t h
the pH adjusted to 7.4 at 37
◦C. The coronary perfusion
pressure was measured by a pressure transducer (Elunit,
Yugoslavia) and recorded by a Kipp & Zonen chart recorder
(UK). The electrical pacing of the isolated hearts (3V, 2ms,
300bpm) was performed with the electrodes placed on the
r i g h ta u r i c l e sn e a rS An o d e .
After the equilibration period (20 minutes), the ischemic
vasodilation was induced by the interruption of coronary
inﬂow (global ischemia) for 60 seconds. Two to three bouts
of the ischemic vasodilation were induced in each heart,
both without (the control group, n = 10) and with glucagon
solution (the test group, n = 10) approximately 15–20
minutes between the interruptions of the coronary inﬂow.
Glucagon (Sigma, USA) was added in the physiological solu-
tion in the ﬁnal concentration of 400nM, at least 2 minutes
before the occlusion, and the addition continued during the
reperfusion, until 2 minutes after the reestablishment of the
coronary pressure to the preischemic level. The samples of
the venous eﬄuent were continuously collected during the
reperfusion period and prepared for further analysis: the
determination of the histamine concentration, and the levels
of NO and TBARS.
ThehistamineconcentrationwasmeasuredusingShore’s
ﬂuorometric method [29].
After the coronary occlusion, the coronary pressure
decreased near to zero. Following the period of ischemia, the
coronaryﬂowwasreestablished(thereperfusionperiod)and
the changes in the coronary perfusion pressure (CPP) versus
time were recorded.
TheexperimentallyrecordeddependenceofCPPontime
duringthereperfusionperiodwasﬁttedusinganexponential
mathematical function:
y = b1

1 −e−b2x

,( 1 )
where y was the CPP (in mmHg), x was the time (in s), and
b1 and b2 were the coeﬃcients of this relationship:
(i) b1 has units of pressure, and
(ii) b2 has units of time−1.
This function is shown in the Figure 1. as the CPP
versus time curve. The constant b1 represents the maximumJournal of Biomedicine and Biotechnology 3
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Figure 1: Exponential curve y = b1(1 −e−b2x).
developedpressure,thatis,thepressurecorrespondingtothe
alternate steady state.
We introduced a dominant time constant (T) as the time
value corresponding to the cross section point between the
asymptote of the exponential curve and the tangent of the
exponential curve at the zero point. This constant results
from the following function (1):
T =
1
b2
. (2)
We considered that the alternate steady state was reached
for t = 5T (t = time), because in this case, e−t/T = e−5 ≈ 0,
and y ≈ b1.
Beside the time duration of the CPP restoration (or the
ﬂow restoration), the area above the CPP or the ﬂow curve
hadbeencommonlyusedastheparameterfortheestimation
of CPP or the ﬂow restoration after the ischemic period,
by means of the conventional mathematical methods. In
this paper, the area above the experimental CPP curve was
deﬁned as eAIV (area of ischemic vasodilation).
The area above the ﬁtted curve-fAIV (Figure 2)c a nb e
deﬁned by the following function (3):
f AIV =
 ∞
0

b1 − b1

1 −e−b2x

(3)
and calculated from the following function (4):
fAIV =
b1
b2
. (4)
2.1. Nitrite Determination. Nitric oxide was assessed as
nitrite and quantiﬁed by the spectrophotometric method
using the Griess-reagent. 0.5mL of the perfusate was pre-
cipitated with 200μL of 30% sulfosalicylic acid, vortexed
for 30 minutes and centrifuged at 3000×g. The equal
volumes of the supernatant and Griess’s reagent, containing
1% sulfanilamide in 5% phosphoric acid/0.1% naphthalene
ethylenediamine-dihydrochloride were added and incubated
for 10 minutes in the dark and read at 543nmol/l. The nitrite
levels were calculated using sodium nitrite as the standard
[30].
2.2. Index of Lipid Peroxidation (Thiobarbituric Acid Reactive
Substances-TBARS). The degree of lipid peroxidation in the
Table 1: Histamine concentrations in the control (without
glucagon) and test (in the presence of glucagon) groups taken
during preischemic and reperfusion periods.
Control group Test group
Histamine
concentration in
preischemic period
(μM)
4.6 ± 0.8 ·10
−8 5.1 ±0.6 ·10
−8
Histamine
concentration within
reperfusion period
(μM)
10.4 ±0.9 ·10
−8∗† 6.8 ±0.5 ·10
−8∗†
Values are represented as mean ± S.E.M.
(∗)Representssigniﬁcantlydiﬀerentvaluesbetweencontrolandtestgroups,
P<. 01; n = 10.
(†) Represents signiﬁcantly diﬀerent values between histamine concentra-
tions in preischemic and reperfusion periods, P<. 01; n = 10.
coronary venous eﬄuent was estimated by the measurement
of thiobarbituric acid reactive substances (TBARS) using 1%
TBA (thiobarbituric acid) in 0.05 NaOH incubated with
the coronary eﬄuent at 100
◦Cf o r1 5m i n u t e sa n dr e a da t
530nm. Krebs-Henseleit solution was used as a blank probe
[31].
2.3. Statistical Analysis. Data are presented as mean ±
S.E.M. (standard error of the mean). Statistical analysis was
performedbyusingthemultifactorialanalysisofthevariance
for repeated measurements between the subject factors as
wellasBonferroni-test.P valueslessthan.05wereconsidered
to be signiﬁcant. Also, the data were analyzed using Student’s
t-test, where P value of <. 05 was considered as statistically
signiﬁcant.
3. Results
To investigate the eﬀect of the glucagon on the concentration
of the histamine in the coronary venous eﬄuents, the levels
of histamine were measured both in the control and in
the test groups either in the absence (n = 10) or in the
presence (n = 10) of the glucagon, respectively. Our results
demonstrated no statistically signiﬁcant diﬀerences in the
levels of the histamine concentration both in the control
and the test groups, as shown in the Table 1. On the other
hand, there was a signiﬁcant increase of the histamine release
both in the control (126%) and the test groups (33%) during
the reperfusion period compared to the preischemic levels.
The increase of the histamine concentrations achieved the
maximal values within 30 to 90s in the control group and
within 30 to 60s in the test group during the reperfusion
period. In addition, our results indicated a signiﬁcant
decrease of the histamine release in the presence of glucagon
during the reperfusion period compared to the control
group.
Furthermore, we measured the levels of NO in the
coronary venous eﬄuent, collected both during preischemic
andthereperfusionperiods,bothinthecontrol(n = 10)and
the test (n = 10) groups, as presented in the Figure 3.T h e4 Journal of Biomedicine and Biotechnology
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Figure 2: Restoration of CPP (original trace) in the absence (a) and in the presence (b) of glucagon (fAIV is area of ischemic vasodilation
above the ﬁtted CPP curve).
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Figure 3: NO concentrations in the coronary venous eﬄuent
collected during preischemic and reperfusion period in the control
and test groups. ∗ represents signiﬁcantly diﬀerent values between
corresponding values in control and test groups, P<. 01; n = 10.
results showed the increase of NO concentrations in both
groups during the reperfusion period. Also, the levels of NO
inthetestgroupweresigniﬁcantlyelevated(71%)duringthe
preischemic period in comparison to the control group.
The elevated concentrations of NO in the control group
collected during the reperfusion period showed two peak
values:
(i) the ﬁrst peak was evident 30 seconds following the
reperfusion period with the increase of 187%, and
(ii) the second peak showed 90 seconds following the
reperfusion period with the increase of 221%.
On the other hand, the NO level in the test group
achieved one peak value within ﬁrst 30 seconds of the
reperfusion period. After reaching the peak value, the NO
level in the test group gradually decreased until the end of
the reperfusion period.
Moreover, within ﬁrst 30 seconds of the reperfusion
period, the NO levels in the test group were initially sig-
niﬁcantly higher (60%) but eventually reached signiﬁcantly
lower levels (45%) within ﬁrst 90 seconds of the reperfusion
period, compared to the corresponding NO levels in the
control group.
Next, we investigated the concentrations of TBARS in the
samplescollectedduringboththepreischemicandthereper-
fusion periods, both in the control and in the test groups.
Our results showed that the concentrations of TBARS in
the samples collected during the reperfusion period were
greatly elevated in comparison to the preischemic levels,
both in the control group (202.6%, n = 10) and in the
test group (226.7%, n = 10), as shown in the Table 2.
The highest TBARS concentrations were achieved within the
ﬁrst 30 seconds of the reperfusion period in both groups.
In addition, our results showed no statistically signiﬁcant
diﬀerences in the TBARS levels neither in the control nor
in the test group both during the preischemic and the
reperfusion periods.
Further, we analyzed the experimental CPP-time curves
using a method as described in Materials and Methods.
The values of 5T, the b1 and b2 coeﬃcients of the ﬁtted
experimental data (coeﬃcient of correlation was 0.998 ±
0.002) both in the control (n = 10) and in the test (n =
1) groups were shown in the Table 3. Our analyzed data
indicated signiﬁcant increase of the coeﬃcient b2 in the test
group compared to the control group. However, the 5T valueJournal of Biomedicine and Biotechnology 5
Table 2: TBARS levels in control (without glucagon) and test (in
the presence of glucagon) groups taken during preischemic and
reperfusion periods.
Control group Test group
TBARS concentration
in preischemic period
(mM)
6.49 ±3.44 ·10
−6 5.61 ±3.41 ·10
−6
TBARS concentration
within reperfusion
period (mM)
19.64 ±3.17 ·10
−6 18.33 ±2.15 ·10
−6
Values are represented as mean ± S.E.M (n = 10).
Table 3: Calculated mathematical parameters (b1 and b2)i nt h e
control and test groups, and time within which the maximal
pressure is developed (taken as 5T).
Parameter Control group Test group
b1 54.94 ±4.25 8 .28 ±3.7
b2 0.04 ±0.003 0.062 ±0.004
∗
5T (s) 125.4 ±5.68 1 .7 ±5.2
∗
Values are represented as mean ± S.E.M.
(∗) represents signiﬁcantly diﬀerent values between control and test group,
P<. 01; n = 10.
in the test group was signiﬁcantly lower in comparison to the
value of the control group. Moreover, our results showed no
greatdiﬀerence in b1 coeﬃcientsbetween thecontrolandthe
test groups of the animals.
When analyzing the fAIV in both the control and the test
groups, our results showed that fAIV in the control group
was 1373 ± 33, while in the presence of glucagon this area
was signiﬁcantly lower (940 ± 28). At the same time the
values of eAIV both in the control group (1360 ± 29) and
the test group (951 ± 30) were not signiﬁcantly diﬀerent in
comparison to the corresponding fAIV values.
4. Discussion
The restoration of the coronary perfusion pressure during
the reperfusion period in our experiments had an exponen-
tial form rather than the step function, indicating that the
ischemic vasodilation occurred within this period.
In this study, we investigated the ischemic vasodilation
o ft h ei s o l a t e dr a th e a r t ,a sw e l la st h eN O ,T B A R S ,a n d
histamine concentrations in the coronary venous eﬄuent
either in the presence or in the absence of glucagon. We
used a new approach [12] in the ex vivo experiments
considering not only the end points of the vessels response,
but also the dynamics of this response. In order to elucidate
the mentioned phenomena, we described the dynamic
behavior of the coronary blood vessel during the ischemic
vasodilation by proposing a mathematical relation where
the parameters were evaluated through the relationships of
the coronary pressure-time curves with the experimental
data. The coronary pressure-time curves were ﬁtted using
the simple exponential mathematical function in the way
that both b1 and b2 coeﬃcients had the physical mean-
ing. In this function, the ﬁrst coeﬃcient—b1—numerically
described the maximal developed coronary pressure that
corresponded to the pressure in the alternate steady state.
Thesecondcoeﬃcient—b2—wasrelevantforthedescription
of the vessel transition response between the alternate steady
states. In our previous work [12], we demonstrated that
these coeﬃcients were highly sensitive parameters to the
conditions of the blood vessel dynamics.
The mathematical analysis of the CPP dynamics showed
no signiﬁcant diﬀerences in the b1 coeﬃcients (Table 3)
both in the control and in the test groups of animals.
This result revealed that the maximal coronary perfusion
pressureduringtheischemicvasodilationwassimilarinboth
groups of animals. On the contrary, the b2 coeﬃcient in
the test group was signiﬁcantly higher compared to the b2
coeﬃcient of the control group, indicating the alteration
in the dynamic response during the ischemic vasodilation
in the presence of the glucagon. In addition, the time
interval for the development of the maximal CPP during the
alternate steady state was 125 seconds in the control group
and it was signiﬁcantly higher compared to the maximal
CPP developmental period of 82 seconds in the test group.
Therefore, these results demonstrated a faster increase of the
coronary pressure in the glucagon-treated hearts (Table 3).
T h ev a l u e so ffAIV in the presence of the glucagon
were signiﬁcantly lower compared to the fAIV values of
the control group conﬁrming the glucagon alteration of
the ischemic vasodilation in our experimental design. On
the other hand, the fAIV values were not notably diﬀerent
from the eAIV values in both groups, demonstrating the
logical consequence of the extremely high coeﬃcient of the
correlation (R2 = 0.998 ± 0.002) between the ﬁtted and the
experimental CPP curves (Figure 2).
In addition, we calculated the Index of lipid peroxidation
by measuring the levels of thiobarbituric acid reactive
substances-TBARS (the known markers of the oxidative
stress). Our data demonstrated signiﬁcantly the elevated
levels of TBARS within 2 minutes of the reperfusion both in
the control and the test groups compared to the preischemic
levels (Table 2). These ﬁndings were in accordance with the
previous reports [1, 8, 32]. Also, our data demonstrated
no apparent diﬀerences in the TBARS levels between the
control and the test groups, during both the preischemic and
the ischemia-reperfusion periods. These results indicated
that the glucagon administration did not aﬀect the TBARS
levels in the isolated rat heart during both the preischemic
and the ischemia-reperfusion periods in our experimental
conditions.
Investigation of the NO level both before and during the
ischemic vasodilation in the presence and in the absence of
the glucagon clearly demonstrated that:
(1) the NO levels during the preischemic period were
signiﬁcantly elevated in the presence of glucagon
compared to the control group;
(2) the NO level within the ﬁrst 30 seconds of the
reperfusion period was signiﬁcantly higher, and after
90 seconds it was signiﬁcantly lower in the test group,
compared to the corresponding NO levels in the
control group.6 Journal of Biomedicine and Biotechnology
These ﬁndings were similar to the previous data report-
ing that the nitrite levels were higher under the glucagon
treatment in the rat hepatocyte culture [33] and that the NO
levels increased during the ischemia-reperfusion conditions,
as well [7, 9, 34, 35]. Our experimental data also showed no
apparent changes in the preischemic CPP values measured
continuously during the glucagon administration. These
results indicated that the elevated preischemic NO level in
the test group did not signiﬁcantly aﬀect the coronary vessel
diameters in our experimental conditions. Even though the
elevated preischemic NO level did not have the signiﬁcant
eﬀects on the histamine release, its role in inﬂuencing
the mast cells stabilization [6] and consequently reducing
the histamine release in the test group during ischemic
vasodilation should not be neglected.
Our previous ﬁndings [12] demonstrated the inﬂuence
of L-arginine on the faster development of the perfusion
pressure in the isolated blood vessels. Although L-arginine
in the previous investigation relaxed the smooth muscle in
the blood vessel wall, the introduction of the hydrostatic
pressure caused the blood vessel wall to become more rigid.
These ﬁndings indicated that the increase of the NO release
might not only induce the vasodilation, but it also might
aﬀect the biomechanical properties of the blood vessel wall.
Eventhoughthevasodilation occurred atthealternatesteady
states, the transient or the dynamic response of the blood
vessel showed faster development of the pressure.
It is well known that the histamine release is elevated
during the ischemic vasodilation and its concentration is
increased during the ischemia [36]. Our results in this study
conﬁrmed these ﬁndings. Also, our results showed that
the histamine liberation during the ischemic vasodilation
was signiﬁcantly reduced in the presence of glucagon in
the isolated rat heart. These data were in the accordance
with the previous reports describing the inﬂuence of the
glucagon on the inhibition of the histamine release during
the anaphylactic response in a guinea-pig isolated heart and
the protective eﬀects of the glucagon pretreatment during
cardiac anaphylaxis [27].
Changes in both NO and histamine releases during both
the ischemic vasodilation and the coronary autoregulation
suggested a positive feedback between NO and histamine
[11]. This may explain the biphasic NO release in our
control group. The initial increase of NO within the ﬁrst 30
seconds of the reperfusion period may lead to the increase
of histamine release reaching the peak values between 30–
90 seconds. Furthermore, the histamine stimulation of the
endothelial histamine receptors produced the second peak
of the NO release, by positive feedback mechanism, after 90
seconds of the reperfusion.
As mentioned earlier, the NO level during the preis-
chemic period was signiﬁcantly elevated in the presence of
glucagon. At the same time, there was neither a change
in the CPP nor in the basal (preischemic) histamine
concentrations. Even though the preischemic NO level was
signiﬁcantly elevated, the amount of NO released seemed to
beinsuﬃcienttodilatethecoronarybloodvessels,sincethere
wasnochangeintheCPPatthattime.Ontheotherhand,the
increased amount of NO might be suﬃcient to stabilize mast
cells, therefore inﬂuencing the lack of the positive feedback
relationship between NO and the histamine in the presence
of glucagon. This could be the cause of the signiﬁcantly
lower NO release in the test group 90 seconds following the
ischemic vasodilation.
5. Conclusions
In the summary, the inﬂuence of the glucagon on the
dynamic responses of the coronary vessels of the isolated
rat heart was uncertain during the ischemic vasodilation.
In this study, our results showed a faster restoration of the
coronary perfusion pressure during the reperfusion period
in the presence of glucagon compared to the control group.
Therefore, one of the possible postulated mechanism(s)
explaining this process could be as following:
(i) the glucagon increases NO release both during the
preischemic period and within the ﬁrst 30 seconds of
the ischemic vasodilation;
(ii) NO stabilizes the mast cells and prevents the his-
tamine release during the ischemic vasodilation;
(iii) further, the decreased histamine release then leads
to the attenuated stimulation of the endothelial
histamine receptor (H1) and consequent decrease of
the NO release, thus switching oﬀ this vasodilatory
mechanism;
(iv) simultaneously, the decreased histamine release leads
to the attenuation of the H2/H3 mediated coronary
vasodilation in the presence of glucagon;
(v) as a result, the duration of the ischemic vasodilation
is signiﬁcantly shorter in the presence of glucagons;
(vi) moreover, the increased NO release within the ﬁrst
30 seconds of the ischemic vasodilation leads to the
vasodilation in the presence of glucagon that in turn
may also increase the rigidity of the coronary blood
vessels, generating the faster development of CPP.
Finally, even though the mechanism(s) of the glucagon
inﬂuences on the coronary vessels during the ischemic
vasodilationisstillunclear,ourresultsclearlyindicatethekey
involvement of both histamine and NO during this process.
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